Farmacologia_FMABC_News

29/09/2026

A FDA adicionou um alerta em destaque à bula da injeção de carboximaltose férrica (Injectafer) para descrever o risco de baixos níveis de fosfato.

17/09/2026

15/08/2026

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases

Inhaled biologics to treat lung diseases have an extensive history. This is counterbalanced by the limited products that have reached the commercialization stage of development despite the numerous disease states and targets that may be suitable for the delivery of proteins, peptides, or nucleic aci...

12/08/2026

Physiological mechanisms and therapeutic targets in chronic cough

https://pmc.ncbi.nlm.nih.gov/articles/PMC13447969/?fbclid=IwdGRleATpjy5wZG9mBWZkaWQWUMW17FDXMRelAE8Xepvw0sVjwkLAqmV4dG4DYWVtAjExAHNydGMGYXBwX2lkCjY2Mjg1NjgzNzkAAR6tplhS0g6dyLqC8e5seM9kQiomn6gGF4Kb0uOt8tLmW_4M2JvbckaUMUMTJg_aem_a2VmbnUZzCCUmzxM5f16YQ

Cough is a vital defensive reflex that safeguards the airways; however, it can become maladaptive and pathological. Chronic cough (>8 weeks in duration) affects up to 10% of the global adult population and is associated with considerable health ...

27/07/2026

Otsuka Receives FDA Approval for First-in-Class SIMTRIYO® (centanafadine) for the Treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in Adults and Pediatric Patients Aged 6 Years and Older

Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has granted approval of SIMTRIYO® (centanafadine), a once-daily extended-release capsule for the treatment of attention-deficit hyperactiv...

17/07/2026

FDA Approves First Oral Therapy that Inhibits Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) to Lower Bad Cholesterol in Adults with High Cholesterol

FDA has approved Lipfendra. Read more.

14/07/2026

Doctors vs. Algorithms: Physicians, too, struggle to learn from evidence that contradicts AI suggestions

Author summary Artificial Intelligence (AI) is now widely used in various fields, including clinical practice, where AI systems assist in classifying patients for diagnosis and treatment. However, these AI-based patient classification systems can sometimes use incorrect, outdated, or incomplete data...

23/06/2026

New Therapies for Sarcoidosis: Molecular and Pathophysiological Basis

https://www.mdpi.com/1422-0067/27/12/5335?fbclid=IwdGRleASn39xleHRuA2FlbQIxMQBzcnRjBmFwcF9pZAo2NjI4NTY4Mzc5AAEeEJgMOw-i5qI869-_ONXQVsNgoRbELIKrMhieOP0II5yEr3k6i9DEt0eNT20_aem_hN7O5u2yCnf0jgUeLTudzg

Sarcoidosis is a multisystem granulomatous disorder of uncertain origin which still presents major therapeutic dilemmas. Longstanding dependence on corticosteroids, while effective for acute inflammation, carries considerable adverse effects over time. Advances in deciphering sarcoidosis pathobiolog...

23/05/2026

https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-chronic-hepatitis-delta-virus-hdv-infection

https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-chronic-hepatitis-delta-virus-hdv-infection

Today, the U.S. Food and Drug Administration approved Hepcludex (bulevirtide-gmod) injection to treat chronic hepatitis delta virus (HDV) infection in adults without cirrhosis (advanced liver scarring) or with compensated cirrhosis.

14/05/2026

1979 - Palestra de encerramento de Albert Sabin no Comuabc